Value investing is easily one of the most popular ways to find great stocks in any market environment. After all, who wouldn’t want to find stocks that are either flying under the radar and are compelling buys, or offer up tantalizing discounts when compared to fair value?
One way to find these companies is by looking at several key metrics and financial ratios, many of which are crucial in the value stock selection process. Let’s put Amdocs Limited ( DOX Quick Quote DOX - Free Report) stock into this equation and find out if it is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks: PE Ratio
A key metric that value investors always look at is the Price to Earnings Ratio, or PE for short. This shows us how much investors are willing to pay for each dollar of earnings in a given stock, and is easily one of the most popular financial ratios in the world. The best use of the PE ratio is to compare the stock’s current PE ratio with: a) where this ratio has been in the past; b) how it compares to the average for the industry/sector; and c) how it compares to the market as a whole.
On this front, Amdocs has a trailing twelve months PE ratio of 17.65, as you can see in the chart below: This level actually compares pretty favorably with the market at large, as the PE for the S&P 500 stands at about 27.61. If we focus on the long-term PE trend, Amdocs’ current PE level puts it slightly above its midpoint over the past five years. Further, the stock’s PE also compares favorably with the industry’s trailing twelve months PE ratio, which stands at 41.09. At the very least, this indicates that the stock is relatively undervalued right now, compared to its peers. We should also point out that Amdocs has a forward PE ratio (price relative to this year’s earnings) of just 15.89, so it is fair to say that a slightly more value-oriented path may be ahead for Amdocs stock in the near term too. P/S Ratio
Another key metric to note is the Price/Sales ratio. This approach compares a given stock’s price to its total sales, where a lower reading is generally considered better. Some people like this metric more than other value-focused ones because it looks at sales, something that is far harder to manipulate with accounting tricks than earnings.
Right now, Amdocs has a P/S ratio of about 2.34. This is lower than the S&P 500 average, which comes in at 5.02 right now. Also, as we can see in the chart below, this is below the highs for this stock in particular over the past few years. As we can see, the stock is trading near its median value for the time period from a P/S metric. This does not provide us with a conclusive direction as to the relative valuation of the stock in comparison to its historical trend. Broad Value Outlook
In aggregate, Amdocs currently has a Zacks Value Style Score of A, putting it into the top 20% of all stocks we cover from this look. This makes Amdocs a solid choice for value investors, and some of its other key metrics make this pretty clear too.
For example, the PEG ratio for Amdocs is 1.59, a level that is lower than the industry average of 2.01. The PEG ratio is a modified PE ratio that takes into account the stock’s earnings growth rate. Additionally, its P/CF ratio (another great indicator of value) comes in at 13.29, which is better than the industry average of 14.35. Clearly, DOX is a solid choice on the value front from multiple angles. What About the Stock Overall?
Though Amdocs might be a good choice for value investors, there are plenty of other factors to consider before investing in this name. In particular, it is worth noting that the company has a Growth grade of A and a Momentum score of D. This gives DOX a Zacks VGM score—or its overarching fundamental grade—of A. (You can read more about the Zacks Style Scores
here >>) Meanwhile, the company’s recent earnings estimates have been mostly tending lower. The current fiscal quarter has seen no estimates go higher in the past sixty days compared to two lower, while the fiscal full year estimate has seen one upward and three downward revisions in the same time period. As a result, the current fiscal quarter consensus estimate has fallen by 4.2% in the past two months, while the fiscal full year estimate has inched lower by 0.6%. You can see the consensus estimate trend and recent price action for the stock in the chart below:
This negative trend is why the stock has just a Zacks Rank #3 (Hold) despite strong value metrics and why we are looking for in-line performance from the company in the near term.
Amdocs is an inspired choice for value investors, as it is hard to beat its incredible lineup of statistics on this front. However, with a sluggish industry rank (among the bottom 35%) and a Zacks Rank #3, it is hard to get too excited about this company overall.
So, value investors might want to wait for estimates, analyst sentiment and broader factors to turn around in this name first, but once that happens, this stock could be a compelling pick. Biggest Tech Breakthrough in a Generation
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.
A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 8 stocks to watch. The report is only available for a limited time. See 8 breakthrough stocks now>>